2016
DOI: 10.1002/hed.24522
|View full text |Cite
|
Sign up to set email alerts
|

Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor for the treatment of unresected stage IIIB/IIIC/IV melanoma

Abstract: BackgroundCutaneous head and neck melanoma has poor outcomes and limited treatment options. In OPTiM, a phase 3 study in patients with unresectable stage IIIB/IIIC/IV melanoma, intralesional administration of the oncolytic virus talimogene laherparepvec improved durable response rate (DRR; continuous response ≥6 months) compared with subcutaneous granulocyte‐macrophage colony‐stimulating factor (GM‐CSF).MethodsRetrospective review of OPTiM identified patients with cutaneous head and neck melanoma given talimog… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
46
0

Year Published

2016
2016
2022
2022

Publication Types

Select...
6
2
1

Relationship

0
9

Authors

Journals

citations
Cited by 58 publications
(46 citation statements)
references
References 27 publications
0
46
0
Order By: Relevance
“…In addition, there is growing recognition that oncolytic viruses have the potential to generate new antitumor host immune responses (23). For example, a conditionally replicative modified herpes viral vector expressing GM-CSF was the first oncolytic virus approved by the FDA, after demonstrating efficacy in a phase III clinical study in patients with advanced unresectable melanoma (24,25). Further, recent data using this vector (talimogene laherparepvec)…”
Section: Introductionmentioning
confidence: 99%
“…In addition, there is growing recognition that oncolytic viruses have the potential to generate new antitumor host immune responses (23). For example, a conditionally replicative modified herpes viral vector expressing GM-CSF was the first oncolytic virus approved by the FDA, after demonstrating efficacy in a phase III clinical study in patients with advanced unresectable melanoma (24,25). Further, recent data using this vector (talimogene laherparepvec)…”
Section: Introductionmentioning
confidence: 99%
“…In conclusion, the early detection of distant metastases is of particular importance for patients with cutaneous melanoma in the head and neck region, as surgical resection can be limited by both technical and cosmetic concerns and regional treatment options may be limited due to anatomic site. 36,37 Furthermore, regional head and neck melanoma is often well controlled by operation (the head and neck was the only site for which completion node dissection offered improved OS in the MSLT-II trial). 38 Thus, the addition of the 31-GEP test to standard staging offers the opportunity to complement node status and identify more patients at risk for distant metastasis and death who could potentially benefit from more aggressive surveillance and earlier therapeutic intervention, [34][35][36] at a point when these treatments are most effective.…”
Section: Discussionmentioning
confidence: 99%
“…Clearly, adenovirus-based vaccine development and gene therapy has a longer history, which has generated a multitude [130] of vector improvements and also resulted a number of clinical trials [131,132]. Similarly, herpes simplex virus (HSV) vectors have been frequently applied and HSV-GM-CSF have, for instance, been subjected to phase I−III human clinical trials in glioblastoma and melanoma patients [133]. HSV vectors were recently approved by the FDA for use in standard patient care [134].…”
Section: Discussionmentioning
confidence: 99%